期刊文献+

活化的蛋白激酶C受体1在非小细胞肺癌中的表达及意义 被引量:7

Expression and significance of receptor of activated kinase 1 in non-small cell lung carcinoma
暂未订购
导出
摘要 目的研究活化的蛋白激酶C受体1(RACK1)在非小细胞肺癌(NSCLC)中的表达及意义。方法采用免疫组织化学EnVision法检测RACK1及甲状腺转录因子-1(TTF-1)蛋白在123例NSCLC(包括组织学标本80份和胸腔积液细胞学标本43份)和50份正常肺组织中的表达情况。结果①RACK1和TTF-1蛋白在NSCLC癌组织中的阳性率分别为48.8%和42.5%,与正常肺组织阳性率4.0%和100.0%相比,差异均具有统计学意义(P<0.05)。在癌组织学标本中,RACK1和TTF-1蛋白在肺腺癌中的阳性率分别为87.5%和80.0%。在细胞学标本中,RACK1和TTF-1蛋白在肺腺癌中的阳性率分别为94.1%和85.3%。RACK1和TTF-1在肺腺癌中的表达率明显高于鳞癌和其他类型,其表达与组织学类型相关(P<0.05)。②RACK1蛋白诊断肺腺癌的灵敏度和特异度分别为90.5%和89.8%,TTF-1的灵敏度和特异度分别82.4%和95.9%。③在40例肺腺癌组织中,RACK1蛋白的表达与吸烟情况、TNM分期及淋巴结转移有关(P<0.05)。结论 RACK1促进了肺腺癌的发生、发展,其高表达可能提示患者预后不良,可能是较TTF-1更为敏感的肺腺癌诊断标记。 Objective To investigate the expression and significance of the receptor of activated kinase 1 (RACK1) in non-small cell lung cancer (NSCLC). Methods The expression of RACK1 and TFF-1 protein in 123 patients with NSCLC (including 80 histological samples and 43 pleural effusion cytology specimens) and 50 cases of normal lung tissue were examined by immunohistochemistry assay (EnVision technique). Results The positive rates of RACKI and TYF-1 in NSCLC tissues (48.8%, 42.5%) were significantly different from that in normal lung tissues (4.0%, 100.0%) (both P〈0.05). The positive expression rates of RACK1 and TTF-1 were 87.5% and 80.0% in lung adenocareinoma histological samples and 94.1% and 85.3% in the pleural effusion due to lung adenocarcinoma, re- spectively. The expression rates of RACK1 and TFF-1 were significantly higher than in squamous cell carcinoma and other types of lung adenocarcinoma (all P〈0.05). The assay sensitivity and specificity of RACK1 and TTF-1 for the di- agnosis of lung adenoearcinoma were 90.5% and 82.4% as well as 89.8% and 95.9%, respectively. The expression of RACK1 was correlated with the smoking status, TNM stages and lymph metastasis (all P〈0.05) in 40 samples of lung adenocarcinoma. Conclusion RACK1 promotes the oncogenesis and development of lung adenocarcinoma and could be a crucial marker that was more sensitive than TYF-1 indicating a poorer prognosis.
出处 《中国药物与临床》 CAS 2014年第2期154-156,I0001,共4页 Chinese Remedies & Clinics
基金 山西省高校科技创新项目(20131104)
关键词 非小细胞肺 活化的蛋白激酶C受体1 免疫组织化学 Carcinoma, non-small cell lung Receptor of activated C kinase 1 Immunohistochemistry
  • 相关文献

参考文献10

  • 1Jemal A,Bray F,Center MM. Global cancer statistics[J].{H}CA-A Cancer Journal for Clinicians,2011,(2):69-90.
  • 2Ron D,Chen CH,Caidwell J. Cloning of an intracellular re-ceptor for protein kinase C:a homolog of the beta subunit of G protein[J].{H}Proceedings of the National Academy of Sciences(USA),1994,(3):839-843.
  • 3Saito A,Fujii G,Sato Y. Detection of genes expressed in primary colon cancers by in situ hybridization:overexpression of RACK1[J].{H}Molecular pathology,2002,(1):34-39.
  • 4Hellberg CB,Burden-Gulley SM,Pietz GE. Expression of the receptor protein-tyrosine phosphatase,PTPmu,restores Ecad-herin-dependent adhesion in human prostate carcinoma cells[J].{H}Journal of Biological Chemistry,2002,(13):11165-11173.
  • 5Lopez-Bergami P,Habelhah H,Bhoumik A. RACK1 medi-ates activation of JNK by protein kinase C[J].{H}Molecules and Cells,2005,(3):309-320.
  • 6Lopez-Bergami P,Huang C,Goydos JS. Rewired ERK-JNK signaling pathways in melanoma[J].{H}CANCER CELLS,2007,(5):447-460.
  • 7Nagashio R,Sato Y,Matsumoto T. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas[J].Lung Can-cer,2010,(1):54-59.
  • 8Cao XX,Xu JD,Liu XL. RACK1:a superior independent predictor for poor clinical outcome in breast cancer[J].{H}International Journal of Cancer,2010,(5):1172-1179.
  • 9Myklebust LM,Akslen LA,Varhaug JE. Receptor for acti-vated protein C kinase 1 (RACK1)is overexpressed in papillary thyroid carcinoma[J].{H}THYROID,2011,(11):1217-1225.
  • 10Ordó(n)ez NG. Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung:an immunohistochemical study with review of the literature[J].{H}Applied Immunohistochemistry and Molecular Morphology,2012,(6):525-530.

同被引文献43

  • 1鲍伟,刘小奕,许颖,丁李,吴佳皓,李柱南,吴丹.Twist在宫颈鳞癌中的表达及其与临床生物学行为的关系[J].上海交通大学学报(医学版),2011,31(5):547-550. 被引量:3
  • 2Saijo N. Problems involved in the clinical trials for non-small cell lung carcinoma[J]. Cancer Treat Rev, 2012, 38(3): 194-202.
  • 3Tucker ZC, Laguna BA, Moon E, et al. Adjuvant immunotherapy for non-small cell lung cancer[J]. Cancer Treat Rev, 2012, 38(6): 650-661.
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
  • 5Scagliotti G, Novello S, von Pawel J, et al. Phase &#x02162; study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(11): 1835-1842.
  • 6McCahill A, Warwicker J, Bolger GB, et al. The RACK1 scaffold protein:a dynamic cog in cell response mechanisms[J]. Mol Pharmacol, 2002, 62(6): 1261-1273.
  • 7Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction[J]. Oncogene, 2001, 20(44): 6339-6347.
  • 8Zhang W, Cheng GZ, Gong J, et al. RACK1 and CIS mediate the degradation of BimEL in cancer cells[J]. J Biol Chem, 2008, 283(24): 16416-16426.
  • 9Shi S, Deng YZ, Zhao JS, et al. RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway[J]. J Biol Chem, 2012, 287(11): 7845-7858.
  • 10高盈. RACK1对肺腺癌细胞侵袭转移的影响及临床意义[D]. 长沙:中南大学,2013.

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部